Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

AnPac Bio-Medical Science Co

Clever Leaves Holdings Inc

Cosmos Holdings

Corbus Pharmaceuticals Holdings

Nutex Health Inc

Oblong

Penny stocks to watch under $1 right now. The post Good Penny Stocks To Buy Now?

Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that following the recently announced halting of the Company's Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership or sale of one or both of the Company's commercial products SYMJEPI® and ZIMHI®, a merger, sale, or reverse merger of the Company, and/or seeking additional financing.

Adamis Announces Review of Strategic Alternatives

Adamis Pharmaceuticals recently provided an update on Tempol's Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vaccination and the Omicron variant might have influenced the outcomes.

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. The independent Data Safety Monitoring Board (DSMB) recommended that the study be halted early due to lack of efficacy. The DSMB did note that no safety concerns were identified in the subjects that received Tempol. Based on the recommendation from the DSMB, the Company has halted the trial and will now evaluate the unblinded data from the trial to determine the next developmental steps for Tempol.

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke David J. Marguglio - Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer Conference Call Participants Operator Greetings and welcome to the Adamis Pharmaceuticals' Second Quarter 2022 Financial Results Conference Call.

Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript

Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET

Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update. The company's press release concerning its second quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on August 10, 2022, and on its website .

Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

Tantech Hlds

Alkaline Water Company Inc (The)

Are these tips part of your penny stocks trading strategy? The post What to Look For in a Penny Stock in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Look For in a Penny Stock in 2022

ISS Recommends Stockholders Support Key Proposals  Pertaining to a Reverse Stock Split and New Equity Incentive Plan

Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals' Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting

Interim DSMB review expected in late September Interim DSMB review expected in late September

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief Executive Officer David J. Marguglio.

Adamis Pharmaceuticals Issues Letter to Stockholders

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Adamis (ADMP) a New Buy Stock

New Director Named with Significant Executive Management and Financial Leadership Experience New Director Named with Significant Executive Management and Financial Leadership Experience

Adamis Appoints Vickie Reed to Board of Directors

David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET Corporate Participants Robert Uhl - ICR Westwicke Dennis Carlo - President and Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer David Marguglio - Chief Business Officer Conference Call Participants Operator Good evening, and welcome to the Adamis Pharmaceuticals First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2022 Results - Earnings Call Transcript

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 16, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2022 as well as provide a business update. The company's press release concerning its first quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on May 16, 2022, and on its website.

Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

G-III Apparel Group

Pool

Steven Madden

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

5 Winning Stocks to Land on the Overlooked Rising P/E Trick

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript

Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths

US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 31, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2021 as well as provide a business update. The company's press release concerning its fourth quarter and 2021 financial results is expected to be available after 1 p.m. Pacific Time on March 31, 2022, and on its website. The company also expects to file its annual report on Form 10-K for the year ended December 31, 2021 on that date.

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) voluntarily recalls certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level.  The batches are being recalled due to the potential clogging of the needle preventing.

News for Adamis Pharmaceuticals Stock (ADMP)